AMENDED AND RESTATED MATERIAL TRANSFER, OPTION AND RESEARCH LICENSE AGREEMENT between OPIANT PHARMACEUTICALS, INC. and AEGIS THERAPEUTICS, LLCConfidential Treatment • June 8th, 2016 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
This Amended and Restated Material Transfer, Option and Research License Agreement (the “Agreement”) as executed on April 26, 2016 and effective as of December 1st, 2014 (the “Effective Date”), is entered into between Aegis Therapeutics, LLC (“Aegis”), having a place of business at 11770 Bernardo Plaza Court, Suite 353, San Diego, CA 92128, and Opiant Pharmaceuticals, Inc. (f/k/a Lightlake Therapeutics Inc.) (“Opiant”), having a place of business at 401 Wilshire Blvd., 12th Floor, Santa Monica, CA 90401.
